After 50 Years, U.S. Opens The Door To More Cannabis Crops For Scientists
After more than 50 years, the federal government is lifting a roadblock to cannabis research that scientists and advocates say has hindered rigorous studies of the plant and possible drug development.
Since 1968, U.S. researchers have been allowed to use cannabis from only one domestic source: a facility based at the University of Mississippi, through a contract with the National Institute on Drug Abuse (NIDA).
That changed earlier this month, when the Drug Enforcement Administration announced it’s in the process of registering several additional American companies to produce cannabis for medical and scientific purposes.
Stories you may be interested in
Customize Your Patient Notes with Arfinn Med
Joining the text messaging update, the Arfinn Med portal now presents the ability to create note taking templates. This innovative addition will allow physicians to streamline the data and information that they are collecting from patients, resulting in their cases staying aligned and concise. Additionally, through this function, physicians will be able to pick and…
Read More 
More Treatment Options, Better Patient Outcomes
As more states start to pass medical marijuana legislation, patients benefit from having more options available to them regarding their treatment. In fact, a recent study from Columbia University’s Irving Medical Center found that, “States with active medical marijuana laws saw certain opioid prescription rates drop nearly 20 percent compared to states without medical marijuana…
Read More 
New study finds cannabis effective for treating migraines
A study published last month in the Journal of Pain found a statistically significant reduction in migraine and headache symptoms and recurrences among patients who used cannabis for treatment.Smoking cannabis reduced the severity and length of migraine episodes by nearly half. Researchers concluded that headache and migraine severity were reduced by nearly 50% after using cannabis. The study, conducted by researchers…
Read More 
New Feature Updates
It’s a new feature alert! At Arfinn Med we always work to make sure we are the industry leading software platform and EMR for medical cannabis providers and clinics. Keeping with that sentiment, we’ve recently updated two features that have been very popular with Arfinn Med users. Those are the customizable consent and confirmation page…
Read More 
A Message To Our Clients
To Our Clients, First of all, I hope everyone is staying safe and healthy in these unprecedented times. I want to assure you that Arfinn Med has systems in place to ensure that our workflows are not impacted from having staff work remotely and we will continue to provide the same quality product and customer service…
Read More 
Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease
A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More